Efficacy and Safety of Adjunctive Cilostazol to Clopidogrel‐Treated Diabetic Patients With Symptomatic Lower Extremity Artery Disease in the Prevention of Ischemic Vascular Events

Background Type 2 diabetes mellitus is a risk factor for lower extremity arterial disease. Cilostazol expresses antiplatelet, anti‐inflammatory, and vasodilator actions and improves the claudication intermittent symptoms. We investigated the efficacy and safety of adjunctive cilostazol to clopidogre...

Full description

Bibliographic Details
Main Authors: Kallirroi Kalantzi, Nikolaos Tentolouris, Andreas J. Melidonis, Styliani Papadaki, Michail Peroulis, Konstantinos A. Amantos, George Andreopoulos, George I. Bellos, Dimitrios Boutel, Magdalini Bristianou, Dimitrios Chrisis, Nikolaos A. Dimitsikoglou, John Doupis, Chrysoula Georgopoulou, Stergios A. Gkintikas, Styliani Iraklianou, Κonstantinos Kanellas, Kalliopi Kotsa, Theocharis Koufakis, Maria Kouroglou, Anastasios G. Koutsovasilis, Leonidas Lanaras, Eirini Liouri, Charalampos Lixouriotis, Akrivi Lykoudi, Efthymia Mandalaki, Evanthia Papageorgiou, Nikolaos Papanas, Spyridon Rigas, Maria I. Stamatelatou, Ioannis Triantafyllidis, Aikaterini Trikkalinou, Aikaterini N. Tsouka, Ourania Zacharopoulou, Christos Zoupas, Ioannis Tsolakis, Alexandros D. Tselepis
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.120.018184